Reps. Chaffetz and Cummings, the committee’s chairman and a ranking member, respectively, requested documents containing information on revenue from sales of EpiPens, a life-saving severe allergy treatment, since 2007. The representatives are also seeking information on manufacturing costs and reimbursement Mylan receives from Medicare and Medicaid.
Mylan said Monday it plans to release a generic version of EpiPen for $300, half of the price of the brand name product, in response to mounting pressure and criticism from the public, policymakers and medical organizations.
More articles on supply chain:
FDA approves new flu vaccine
The rise of the unbranded drug ad: 5 things to know
FDA fast tracks experimental drug to treat Parkinson’s
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
